The challenges to develop antibody-conjugated nanomedicine products

Abstract

Nanomedicine becomes a key player especially as next generation medicine. Antibody-conjugated nanomedicine could significantly upgrade the treatment and expand application areas. However, there are extensive challenges of manufacturing those formulations as a final drug product. Here we provided the general technical guidance from the initial formulation construction including antibody conjugation to the downstream formulation development. We hope this technical note can help accelerate the translation of productizing the antibody-conjugated nanomedicines.